… of the 146 obese patients receiving apixaban or rivaroxaban for … Twenty-seven (18%) patients
were from Brest University hospital … BMI ranged from 30.1 to 54 kg/m 2 , with 20% patients …

… rivaroxaban doses in bariatric patients. Single doses of 10 mg rivaroxaban resulted in similar
systemic drug … a broader investigation of rivaroxaban in morbidly obese patients, especially …

… During rivaroxaban drug development, several studies were … that investigated rivaroxaban
PK in obese subjects who are … criteria: investigating rivaroxaban PK in obese (BMI ≥ 30 kg/…

… (64.3%), anti-Xa levels were subtherapeutic. The difference between plasma anti-Xa levels
of apixaban and rivaroxaban may be explained by drug-specific differences related to the …

… III drug development were not conducted solely within an obese patient population, each of
the rivaroxaban … on participant body weight and/or BMI. It should be noted that no weight or …

… rivaroxaban use in patients with class III obesity and review available case reports of
measurement of rivaroxaban levels … ISTH guidelines and monitoring drug levels more frequently, …

… healthy subjects both prior to and following bariatric surgery. … use of rivaroxaban in the context
of obesity or bariatric surgery … to rivaroxaban 20 mg once daily, plasma drug concentrations…

… , with rivaroxaban ranked 91 st among the top 300 drug list in … that patients with a morbidly
obese BMI receiving rivaroxaban … rivaroxaban prescribing trends, efficacy, and safety in obese …

… This study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m 2
… may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m 2 . …

… 13 and rivaroxaban levels (data unpublished) in unselected patients taking these drugs with
… found that most patients with weight >120 kg had a peak drug concentration higher than the …